Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187925 | 0.96 | CA2 (0.59) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL31396735 | 0.96 | CA2 (0.59) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL1894893 | 0.94 | CA2 (0.53) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL813789 | 0.93 | CA2 (0.56) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL1004665 | 0.93 | CA2 (0.56) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL93763 | 0.93 | CA2 (0.63) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL9960580 | 0.93 | CA2 (0.63) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL1899775 | 0.92 | CA2 (0.51) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL80648 | 0.89 | CA2 (0.59) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL18334306 | 0.89 | CA2 (0.59) | CA2CA1MAPK1ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8425941-B2 | Powder cosmetic composition | SHISEIDO COMPANY, LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20100239680-A1 | Powder Cosmetic Composition | SHISEIDO COMPANY, LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2044924-A1 | POWDERY COSMETIC | Shiseido Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239680-A1 | Powder Cosmetic Composition | CUTA, ITGB7, PIEZO1 | CA2 2493/4885CA1 3290/4885MAPK1 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.